Eagle's Eye View: Your Weekly CV Update From ACC.org podkast

Aspirin in PCI; Mavacamten in Nonobstructive Cardiomyopathy; Olezarsen and the Treatment of Hypertriglyceridemia

0:00
6:10
Do tyłu o 15 sekund
Do przodu o 15 sekund

Dr. Eagle continues in this week’s View to analyze some of the key clinical content presented at the ESC Congress recently held in Spain. Dr. Eagle examines the TARGET-FIRST trial in which P2Y12-inhibitor monotherapy was compared to dual antiplatelet therapy (DAPT) in patients who have undergone percutaneous coronary intervention (PCI).  He then analyzes the results of the ODYSSEY-HCM trial which explored mavacamten versus placebo in patients with symptomatic nonobstructive hypertrophic cardiomyopathy (HCM). Finally, Dr. Eagle discusses the ESSENCE-TIMI 73b study that looked at olezarsen and its potential for lowering triglycerides in moderate hypertriglyceridemia with elevated cardiovascular risk.  

 Subscribe to Eagle’s Eye View  

Więcej odcinków z kanału "Eagle's Eye View: Your Weekly CV Update From ACC.org"